IGI Logo

Zydus Lifesciences is currently trading at Rs. 522.75, up by 5.45 points or 1.05% from its previous closing of Rs. 517.30 on the BSE.

The scrip opened at Rs. 517.30 and has touched a high and low of Rs. 524.35 and Rs. 516.00 respectively. So far 7326 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 524.35 on 24-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022.

Last one week high and low of the scrip stood at Rs. 524.35 and Rs. 499.50 respectively. The current market cap of the company is Rs. 52361.32 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.02% and 8.00% respectively.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Icosapent Ethyl Capsules, 0.5 g and 1 g (USRLD: Vascepa Capsules, 0.5 g and 1 g).

Icosapent Ethyl Capsules are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Zydus’s Icosapent Ethyl Capsules are not approved for the indication as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease.

Icosapent Ethyl Capsules, 0.5 g and 1 g had annual sales of $1,316 million in the United States. The group now has 365 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.